Affimed Announces Third Quarter 2017 Financial Results and Corporate Update Conference Call

Press Release - October 30, 2017

Download Press Release

Heidelberg, Germany, October 30, 2017 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on November 7, 2017, the Company will release its financial results for the quarter ended September 30, 2017. The Company’s management team will host a conference call to discuss the Company’s financial results and recent corporate developments on Tuesday, November 7, 2017 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3213767.

Local – Amsterdam, the Netherlands: +31 (0)20 716 8295
Local – Copenhagen, Denmark: +45 32 71 16 60
Local – Frankfurt, Germany: +49 (0)69 2222 10625
Local – Zurich, Switzerland: +41 (0)44 580 7214
Local – London, U.K.: +44 (0)20 3427 1907
Local – New York City, U.S.A.: +1 646 254 3366
Local – Paris, France: +33 (0)1 76 77 22 23

An audio webcast of the conference call can be accessed in the Webcasts section on the website. A replay of the webcast will be available on Affimed’s website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit


Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: email hidden; JavaScript is required, email hidden; JavaScript is required